Dr. Manda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
603 N Wilmot Rd
Ste 151
Tucson, AZ 85711Phone+1 520-886-0206Fax+1 520-886-0829
Education & Training
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
- The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 2005 - 2008
- Gandhi Medical CollegeClass of 2002
Certifications & Licensure
- AZ State Medical License 2015 - 2025
- NH State Medical License Active through 2015
- OH State Medical License 2005 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 36 citationsIbrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.Sudhir Manda, Nancy M. Dunbar, Cynthia R. Marx-Wood, Alexey V. Danilov
British Journal of Haematology. 2015-09-01 - 31 citationsZanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke
The Lancet. Haematology. 2023-01-01 - 68 citationsComorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibMax J. Gordon, Michael C. Churnetski, Hamood Alqahtani, Xavier Rivera, Adam Kittai
Cancer. 2018-08-01
Abstracts/Posters
- Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...Sudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...Sudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b StudySudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: